Comparison
Two GHRH-analog options: one an approved drug with real outcome data, one a clinic staple with a thinner record.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy with randomized visceral-fat trials behind it; sermorelin survived as a clinic product whose adult anti-aging claims were never established in trials.
Tesamorelin. Its approval rests on phase 3 randomized trials showing visceral adipose tissue reduction in HIV lipodystrophy, plus a later JAMA liver-fat study. Sermorelin's human literature is mostly pediatric growth-hormone-deficiency diagnostic work; adult wellness use is extrapolation.
Tesamorelin programs mirror the 2 mg daily label; sermorelin programs typically describe 200 to 500 mcg before bed. Both are daily subcutaneous GHRH-analog injections, but only one has a defined, regulator-reviewed schedule.
Tesamorelin is prescription-only and counterfeited because of cost; sermorelin's original brand was discontinued, and FDA confirmed it was not withdrawn for safety or effectiveness: part of why compounded versions persist. Both are WADA-prohibited as GH-releasing factors.
| Dimension | Tesamorelin | Sermorelin |
|---|---|---|
| Overall evidence grade | A | B |
| Evidence label | Strong human evidence | Moderate human evidence |
| Regulatory status | Approved for specific use | Varies by product and jurisdiction |
| Editorial confidence | High confidence | Moderate confidence |
| Efficacy | 4/5 substantial | 3/5 emerging |
| Safety | 3/5 emerging | 2/5 limited |
| Regulatory risk | 1/5 low | 3/5 moderate |
| Product quality risk | 3/5 moderate | 4/5 high |
| Primary claim categories | Approved HIV lipodystrophy context, Visceral adipose tissue evidence, Liver-fat research context, Growth hormone pathway claims, Product-quality and regulatory risks | Historical Geref product context, Pediatric growth hormone deficiency, Pituitary growth hormone reserve evaluation, GHRH pathway claims, Product-quality and eligibility risks |
Tesamorelin has controlled human data for reducing visceral abdominal fat in HIV lipodystrophy. People also discuss it for body composition, cutting, and anti-aging, but those uses sit inside the GH/IGF-1 risk profile and much weaker non-label evidence.
Sermorelin is a historical GHRH reference with narrow pediatric GHD and diagnostic evidence, not a basis for adult anti-aging, body-composition, performance, or wellness claims.
FDA. Egrifta (tesamorelin for injection) NDA approval letter 2010.
Accessed 2026-06-09.
FDA approval letter for Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
DailyMed. EGRIFTA SV- tesamorelin kit prescribing information 2025.
Accessed 2026-06-09.
Current structured product label source for Egrifta SV indication, limitations of use, warnings, pharmacology, and product identity.
PMID:20554713 Accessed 2026-06-09.
Pooled phase 3 randomized placebo-controlled trial evidence in antiretroviral-treated people with HIV and excess abdominal fat.
Accessed 2026-06-09.
Federal Register notice identifying historical Geref treatment and diagnostic uses, discontinued marketing status, and FDA's not-withdrawn-for-safety-or-effectiveness determination.
FDA. Orphan Drug Designations and Approvals: Geref (sermorelin acetate) 1988.
Accessed 2026-06-09.
FDA orphan-designation record for Geref in idiopathic or organic growth hormone deficiency in children with growth failure, including the 1997 marketing-approval date.
WADA. The 2026 Prohibited List: growth hormone-releasing factors 2026.
Accessed 2026-06-09.
WADA lists growth hormone-releasing factors, including tesamorelin, under prohibited peptide hormones, growth factors, related substances, and mimetics.